Press Releases

HAMPTON, N.J. , March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET .

HAMPTON, N.J. , March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci , President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference

HAMPTON, N.J. , March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics , Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the

HAMPTON, N.J. , Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics , Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.

HAMPTON, N.J. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics , Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering.

- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 - - Phase 2 PN study

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid onset within 2 weeks - - Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve

HAMPTON, N.J. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET .

HAMPTON, N.J. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to